RO7565020 for Chronic Hepatitis B
Trial Summary
What is the purpose of this trial?
This trial tests a new drug called RO7565020 to see if it is safe and how it behaves in the body. It includes healthy people and those with chronic hepatitis B. Researchers aim to understand how the drug moves through and affects the body.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop all current medications. However, if you are a healthy volunteer, you must not have used any treatment within 2 weeks or 5 half-lives before the first dose. If you have chronic hepatitis B, you must continue your NUC monotherapy.
What data supports the idea that RO7565020 for Chronic Hepatitis B is an effective treatment?
The available research shows that oral nucleos(t)ide analogues, which include treatments like RO7565020, are recommended as a first choice for chronic hepatitis B because they are effective at reducing the virus in the body and are considered safe. This suggests that RO7565020 could be effective in managing chronic hepatitis B by keeping the virus under control.12345
What safety data is available for RO7565020 treatment in chronic hepatitis B?
The safety profile of nucleos(t)ide analogues, which include treatments like RO7565020, is generally well-tolerated and achieves high rates of viral suppression. Long-term use is common, and while most treatments are safe, some, like adefovir dipivoxil, may cause adverse effects such as nephrotoxicity. Entecavir and tenofovir disoproxil fumarate are preferred first-line agents due to their favorable safety profiles.16789
Eligibility Criteria
This trial is for healthy adults or those with chronic hepatitis B (CHB) who have a BMI of 18-32 kg/m^2. CHB participants must have been positive for HBsAg for at least 6 months and on NUC therapy for over a year without signs of advanced liver disease. People with cirrhosis, suspected cancer, or other significant diseases are excluded.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- NUC treatment (Nucleos(t)ide analogue)
- Placebo (Other)
- RO7565020 (Other)
NUC treatment is already approved in European Union, United States, Canada, Japan for the following indications:
- Chronic hepatitis B
- HIV infection
- Herpes simplex virus infection
- Chronic hepatitis B
- HIV infection
- Herpes simplex virus infection
- Chronic hepatitis B
- HIV infection
- Herpes simplex virus infection
- Chronic hepatitis B
- HIV infection
- Herpes simplex virus infection